-
Phase 1 construction to start at £100m Catalyst Bicester development
Once completed, the new advanced manufacturing and technology business community will total circa 300,000 sq ft and provide workspace for up to 1,750 jobs.
-
House 2 Home Removals moves to Axis Junction 9
House 2 Home (H2H) Oxfordshire has taken on an additional and new unit at Axis J9, Bicester, providing expansion facilities to their existing premises at Axis J9 in Bicester.
-
Sense raises $50m Series B funding for instrument-free product platform
The investment led by Koch Disruptive Technologies helps Sense accelerate its portfolio of products to deliver patient-focused healthcare.
-
OXIS Energy set to make solid-state Lithium-Sulfur cell technology a reality
The Culham Science Centre based company is set to deploy Solid-State Lithium-Sulfur (Li-S) cell and battery systems to its clients and partners worldwide by Autumn 2021.
-
Ocado invests in Oxbotica to develop autonomous integrated mobility solution
Ocado invests in autonomous vehicle software company Oxbotica and announces plans to develop a range of vehicles that will be integrated into the Ocado Smart Platform.
-
Wallingford-based Ecocleen acquires The JPM Group
The successful buyout will enable the group to expand its presence within both established and new sectors whilst growing its nationwide network.
-
Arrival and Origin Global expand to take high-spec logistics hub in Bicester
The high-specification units – with strong sustainability credentials designed to incorporate a ‘carbon zero’ specification – attracted a high calibre of potential tenants.
-
Axis J9 high-spec logistics hub in Bicester is now fully let
Six months after Practical Completion, the substantial scheme in Bicester Oxfordshire of five prominent industrial and warehousing units, has been fully let to Arrival and Origin.
-
Oxford Endovascular raises $10m to develop its origami engineered medical device
The raise will enable the company to complete development work and gain first in-human data through an early feasibility clinical study.
-
Exscientia announces first AI-designed immuno-oncology drug in clinical trials
The company’s technologies and drug-hunting expertise now responsible for the world’s first and second AI-designed drugs to enter Phase I testing.
